Patents by Inventor Matthew L. Fero

Matthew L. Fero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110088106
    Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 14, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
  • Patent number: 7560610
    Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: July 14, 2009
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
  • Publication number: 20040034878
    Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.
    Type: Application
    Filed: April 3, 2003
    Publication date: February 19, 2004
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
  • Patent number: 5958769
    Abstract: Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: September 28, 1999
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero